EyePoint Pharmaceuticals Q4 revenue plunges, net loss widens

EyePoint

04/03/2026 12:09

Overview

Biopharmaceutical firm's Q4 revenue fell sharply yr/yr

Net loss for Q4 widened due to increased operating expenses

Company has over $300 mln cash and investments, funding operations into Q4 2027

Outlook

EyePoint expects topline data for wet AMD trials in mid-2026

Company anticipates topline data for DME trials in second half of 2027

EyePoint's cash reserves expected to fund operations into Q4 2027

Result Drivers

PHASE 3 TRIALS - Increased operating expenses driven by ongoing Phase 3 trials for DURAVYU in wet AMD and DME

REGULATORY READINESS - Focus on regulatory and commercial readiness for DURAVYU supported by strong cash position

UNIQUE POSITIONING - DURAVYU positioned as first-to-market among investigational sustained release treatments for wet AMD and DME

Company press release: ID:nGNX7zLpk1

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q4 Product Sales
$299,000
Q4 Net Income
-$67.61 mln
Q4 Basic EPS
-$0.81
Q4 Operating Expenses
$70.97 mln
Q4 Operating Income
-$70.35 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 12 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

The average consensus recommendation for the pharmaceuticals peer group is "buy"

Wall Street's median 12-month price target for EyePoint Inc is $33.00, about 80.1% above its March 3 closing price of $18.32

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)